Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey


Gediz F., Payzin B. K. , Ecemis S., Guler N., Yilmaz A. F. , Topcugil F., ...More

TRANSFUSION AND APHERESIS SCIENCE, vol.55, no.3, pp.357-362, 2016 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 55 Issue: 3
  • Publication Date: 2016
  • Doi Number: 10.1016/j.transci.2016.09.017
  • Title of Journal : TRANSFUSION AND APHERESIS SCIENCE
  • Page Numbers: pp.357-362

Abstract

Introduction: Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy, which develops as a result of defective activity of the alternative complement pathway and excessive complement activation due to genetic or acquired factors. No satisfactory responses were obtained by plasmapheresis, corticosteroids and fresh frozen plasma (FFP) transfusion. However, promising results are obtained in recent years by eculuzimab treatment, which inhibits C5 activation.